On April 26, Otsuka Pharmaceuticals Co. Ltd. filed a patent infringement suit against Amneal Pharmaceuticals LLC, arguing that Amneal and two of its affiliates, “had infringed Otsuka’s patent by submitting an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA).” The complaint stated that “Amneal has infringed at least one claim of the ‘257 patent by submitting, or causing to be submitted to the FDA, ANDA No. 20-3906 seeking approval for the commercial marketing of Amneal’s generic before the expiration date of the ‘257 patent. Amneal’s generic product will, if approved and marketed, infringe at least one claim of the ‘257 patent.” Otsuka is represented by Finnegan in this matter.
Award/Ranking
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Award/Ranking
The National Law Journal Names Finnegan the Top Intellectual Property Law Department in DC
June 24, 2013
Media Mention
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.